GenScript Reports 27.3% First-Half 2026 Revenue Growth as AI Drug Discovery Business Doubles

Summary

GenScript Biotech reported first-half 2026 revenue of US$404.2 million, representing 27.3% growth, with adjusted net profit surging 203.3%. The company's AI drug discovery business doubled, with Gene-to-Protein generating two-thirds of Life Science Group revenue.